Pokaż uproszczony rekord

dc.contributor.authorBiegański, Przemysław
dc.date.accessioned2024-11-29T09:25:50Z
dc.date.available2024-11-29T09:25:50Z
dc.date.issued2024
dc.identifier.urihttp://hdl.handle.net/11089/53807
dc.description.abstractThe lungs are organs exposed to numerous pathogens, including toxicological factors causing cancer and viral factors responsible for infectious diseases. The area of interest of this PhD thesis pertains to the synthesis of organometallic erlotinib (anticancer drug) conjugates and the examination of these bioconjugates as anticancer agents and SARS-CoV-1/2 entry inhibitors to human cells. Chemically, the goal of my thesis was achieved through the use of Cu(I)-catalyzed or Ru-catalyzed azide-alkyne 1,3-dipolar cycloaddition reactions (CuAAC and RuAAC). These reactions are widely used in medicinal chemistry and molecular biology, which convinced me to choose them as the basic synthetic tools in my research. Erlotinib, a first-generation EGFR inhibitor, can become ineffective due to therapeutically unfavorable mutations in the EGFR receptor gene. To circumvent this problem, subsequent generations of EGFR inhibitors were developed and introduced into clinical practice. The idea behind the synthesis of organometallic conjugates of erlotinib was to introduce a second mechanism of anticancer activity into the molecule, which would be independent of EGFR mutations. This mechanism relies on the organometallic entity and is based on generating oxidative stress in lung cancer cells. I successfully achieved this goal, as some of my compounds exhibited greater activity against erlotinib-resistant lung cancer cells (specifically, cell lines H1650 and H1975) compared to erlotinib itself. Additionally, using click chemistry, I obtained a diferrocenyl derivative of AZT with high activity against lung cancer cells. As in the case of active erlotinib derivatives, the mechanism of its activity was based on the generation of reactive oxygen species and oxidative stress. Another important achievement of my work is the discovery of a ruthenocenyl erlotinib conjugate, which acts as a SARS-CoV-1/2 virus entry inhibitor to human HEK293T cells.pl_PL
dc.description.sponsorshipNarodowe Centrum Nauki w Krakowie (projekt PRELUDIUM 20 UMO-2021/41/N/ST4/00059)pl_PL
dc.language.isoplpl_PL
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectclick chemistrypl_PL
dc.subjecterlotinibpl_PL
dc.subjectAZTpl_PL
dc.subjectlung cancerpl_PL
dc.subjectorganometallic conjugatespl_PL
dc.titleMetaloorganiczne pochodne typu ,,click” erlotynibu oraz AZT – synteza i aktywność biologicznapl_PL
dc.title.alternativeOrganometallic "click" derivatives of erlotinib and AZT - synthesis and biological activitypl_PL
dc.typePhD/Doctoral Dissertationpl_PL
dc.page.number162pl_PL
dc.contributor.authorAffiliationUniwersytet Łódzki, Wydział Chemii, Katedra Chemii Organicznejpl_PL
dc.contributor.authorEmailprzemyslaw.bieganski@edu.uni.lodz.plpl_PL
dc.dissertation.directorKowalski, Konrad
dc.dissertation.reviewerBuchowicz, Włodzimierz
dc.dissertation.reviewerChmielewski, Marcin
dc.dissertation.reviewerŚcianowski, Jacek
dc.date.defence2025-01-30
dc.disciplinenauki chemicznepl_PL


Pliki tej pozycji

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

Pozycja umieszczona jest w następujących kolekcjach

Pokaż uproszczony rekord

Attribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe
Poza zaznaczonymi wyjątkami, licencja tej pozycji opisana jest jako Attribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe